Vireo Growth (VREOF) Restructuring Costs (2020 - 2026)
Vireo Growth (VREOF) reported Restructuring Costs of $7.2 million for Q1 2026, up 620.0% on a YoY basis from $1.0 million in Q1 2025, and down 46.95% sequentially from $13.6 million in Q4 2025.
Vireo Growth (VREOF) Restructuring Costs (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Restructuring Costs data on file, last reported at $7.2 million in Q1 2026.
- For the quarter ending Q1 2026, Restructuring Costs rose 620.0% year-over-year to $7.2 million; the trailing twelve-month figure through Mar 2026 stood at $24.9 million (up 495.5% YoY), and the FY2025 full-year result was $20.4 million, up 351.83% from the prior year.
- Restructuring Costs slipped to $7.2 million in Q1 2026, from $13.6 million in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $13.6 million in Q4 2025 to a low of $182602.0 in Q4 2024.
- A 5-year average of $2.5 million and a median of $1.6 million in 2024 frame the typical range for Restructuring Costs.
- Across the five-year window, Restructuring Costs sank 79.7% in 2024 and surged 7332.89% in 2025, its largest moves.
- Tracing VREOF's Restructuring Costs over 5 years: stood at $1.5 million in 2022, then plunged by 40.58% to $899519.0 in 2023, then slumped by 79.7% to $182602.0 in 2024, then surged by 7332.89% to $13.6 million in 2025, then tumbled by 46.95% to $7.2 million in 2026.
- Business Quant data shows VREOF's Restructuring Costs at $7.2 million in Q1 2026, $13.6 million in Q4 2025, and $803724.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.20 Mn |
| Dec 31, 2025 | 13.57 Mn |
| Sep 30, 2025 | 803,724.00 |
| Jun 30, 2025 | 3.34 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Dec 31, 2024 | 182,602.00 |
| Sep 30, 2024 | 1.57 Mn |
| Jun 30, 2024 | 1.43 Mn |
| Mar 31, 2024 | 1.32 Mn |
| Dec 31, 2023 | 899,519.00 |
| Sep 30, 2023 | 1.40 Mn |
| Jun 30, 2023 | 1.59 Mn |
| Mar 31, 2023 | 1.61 Mn |
| Dec 31, 2022 | 1.51 Mn |
| Sep 30, 2022 | 1.84 Mn |
| Jun 30, 2022 | 2.10 Mn |
| Mar 31, 2022 | 1.95 Mn |
| Dec 31, 2021 | 1.75 Mn |
| Sep 30, 2021 | 2.06 Mn |
| Jun 30, 2021 | 2.34 Mn |